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To the Editor:
Recently Mahadeo et al. [1] reported interesting results
of their novel conditioning regimen for patients with
nonmalignant genetic diseases. In the article the authors
used mAb alemtuzumab in a total dose of 52 mg/m2 on
days 8, 9, and 10 before the date of transplant. Pharma-
cokinetic studies were obtained on days 7, 14, 21, and 28
for half of the patients in this study and resulted in no
reported dose modiﬁcations. Although the authors re-
ported median time to clearance of alemtuzumab to be 14
days (range, 3 to 21 days), inclusion of descriptive phar-
macokinetic curves for these immune naive participants
would have aided the understanding of in vivo pharma-
cology of the mAb.
Alemtuzumab, a potent CD52 inhibitor that causes in vivo
T cell depletion in recipients, has been used in various
reduced-intensity conditioning (RIC) regimens at varying
times during conditioning [2-4]. Although there is plentiful
pharmacokinetic data for this mAb in the adult and pediatric
transplant recipients for malignant conditions [5,6], few
studies have reported measuring these levels in recipients
for nonmalignant disorders.
Unlike the patients in this study, many patients receiving
other RIC for nonmalignant diseases have seen increased
rates of failure to engraftment. The pharmacokinetic data
from this study could have been useful in studying
treatment-related outcome for other and future studies.
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http://dx.doi.org/10.1016/j.bbmt.2015.04.013Various studies have used alemtuzumab recently for pa-
tients with nonmalignant disorders. Adequate timing of
alemtuzumab is key for optimum outcome as recently
demonstrated by us [7]. Alemtuzumab clearance depends
on the actual dose administered, the total number of
CD52 binding sites, the hepatic function, and the mono-
cyteemacrophage system [8]. Today’s rapidly evolving era of
newer RIC regimens for nonmalignant disorders call for well-
done pharmacokinetic studies to identify optimum timing
and dosage that can have signiﬁcant therapeutic implications
for these patients.
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